These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28154202)

  • 1. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
    Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
    Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
    Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
    Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.
    Shimura T; Toden S; Komarova NL; Boland C; Wodarz D; Goel A
    Carcinogenesis; 2020 Jul; 41(6):751-760. PubMed ID: 31904094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
    Henry WS; Laszewski T; Tsang T; Beca F; Beck AH; McAllister SS; Toker A
    Cancer Res; 2017 Feb; 77(3):790-801. PubMed ID: 27940576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
    Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
    Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
    Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
    Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
    Wang Y; Tang Q; Li M; Jiang S; Wang X
    Biochem Biophys Res Commun; 2014 Feb; 444(2):199-204. PubMed ID: 24440701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in
    Miller SA; Policastro RA; Savant SS; Sriramkumar S; Ding N; Lu X; Mohammad HP; Cao S; Kalin JH; Cole PA; Zentner GE; O'Hagan HM
    Mol Cancer Res; 2020 Feb; 18(2):264-277. PubMed ID: 31704733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
    Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
    Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
    Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
    Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin exerts high anti-cancer activity in
    Gu M; Nishihara R; Chen Y; Li W; Shi Y; Masugi Y; Hamada T; Kosumi K; Liu L; da Silva A; Nowak JA; Twombly T; Du C; Koh H; Li W; Meyerhardt JA; Wolpin BM; Giannakis M; Aguirre AJ; Bass AJ; Drew DA; Chan AT; Fuchs CS; Qian ZR; Ogino S
    Oncotarget; 2017 Oct; 8(50):87379-87389. PubMed ID: 29152088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.
    Hall DCN; Benndorf RA
    Cell Mol Life Sci; 2022 Jul; 79(7):393. PubMed ID: 35780223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
    Turturro SB; Najor MS; Ruby CE; Cobleigh MA; Abukhdeir AM
    Breast Cancer Res Treat; 2016 Feb; 156(1):33-43. PubMed ID: 26915040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
    Bäumer N; Rehkämper J; Appel N; Terheyden L; Hartmann W; Wardelmann E; Buchholz F; Müller-Tidow C; Berdel WE; Bäumer S
    PLoS One; 2018; 13(7):e0200163. PubMed ID: 30001368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
    Zhao Y; Feng X; Chen Y; Selfridge JE; Gorityala S; Du Z; Wang JM; Hao Y; Cioffi G; Conlon RA; Barnholtz-Sloan JS; Saltzman J; Krishnamurthi SS; Vinayak S; Veigl M; Xu Y; Bajor DL; Markowitz SD; Meropol NJ; Eads JR; Wang Z
    Cancer Res; 2020 Nov; 80(21):4815-4827. PubMed ID: 32907836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.